SE0300959D0 - Methods for predicting therapeutic response to agents acting on the growth hormone receptor - Google Patents

Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Info

Publication number
SE0300959D0
SE0300959D0 SE0300959A SE0300959A SE0300959D0 SE 0300959 D0 SE0300959 D0 SE 0300959D0 SE 0300959 A SE0300959 A SE 0300959A SE 0300959 A SE0300959 A SE 0300959A SE 0300959 D0 SE0300959 D0 SE 0300959D0
Authority
SE
Sweden
Prior art keywords
methods
growth hormone
hormone receptor
therapeutic response
agents acting
Prior art date
Application number
SE0300959A
Other languages
English (en)
Swedish (sv)
Inventor
Pierre Bougneres
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SE0300959D0 publication Critical patent/SE0300959D0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
SE0300959A 2002-12-19 2003-04-02 Methods for predicting therapeutic response to agents acting on the growth hormone receptor SE0300959D0 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43486102P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
SE0300959D0 true SE0300959D0 (sv) 2003-04-02

Family

ID=23725994

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300959A SE0300959D0 (sv) 2002-12-19 2003-04-02 Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Country Status (12)

Country Link
US (1) US20040180358A1 (zh)
EP (1) EP1572738A1 (zh)
JP (1) JP2006525785A (zh)
KR (1) KR20050085855A (zh)
CN (1) CN1747968A (zh)
AU (1) AU2003278503A1 (zh)
CA (1) CA2510045A1 (zh)
HR (1) HRP20050563A2 (zh)
NO (1) NO20053490L (zh)
RU (1) RU2005122665A (zh)
SE (1) SE0300959D0 (zh)
WO (1) WO2004056864A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766067A1 (en) * 2004-07-08 2007-03-28 Pharmacia & Upjohn Company LLC Methods for predicting therapeutic response to agents acting on the growth hormone receptor
GB0600122D0 (en) * 2006-01-05 2006-02-15 Univ Cardiff Mutation in the growth hormone receptor
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
SG10201704777RA (en) * 2009-06-08 2017-07-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
US20150133383A1 (en) * 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN103014007A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼α-乳白蛋白基因、重组蛋白及其克隆方法
CN103014005A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼a-fabp蛋白基因、重组蛋白及其克隆方法
CN103014008A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼ghr蛋白基因、重组蛋白及其克隆方法
CN112322657B (zh) * 2020-11-12 2023-04-25 浙江新码生物医药有限公司 一种人生长激素的体外活性检测方法
CA3222510A1 (en) 2021-06-18 2022-12-22 Peptidream Inc. Ghr-binding pending peptide and composition comprising same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
AU723494B2 (en) * 1996-02-13 2000-08-31 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
US6080911A (en) * 1997-04-15 2000-06-27 Ohio University Mice models of growth hormone insensitivity

Also Published As

Publication number Publication date
HRP20050563A2 (en) 2005-12-31
AU2003278503A1 (en) 2004-07-14
NO20053490L (no) 2005-09-16
NO20053490D0 (no) 2005-07-18
KR20050085855A (ko) 2005-08-29
CN1747968A (zh) 2006-03-15
JP2006525785A (ja) 2006-11-16
WO2004056864A1 (en) 2004-07-08
CA2510045A1 (en) 2004-07-08
EP1572738A1 (en) 2005-09-14
RU2005122665A (ru) 2006-01-20
US20040180358A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
NO20053490L (no) Methods for prediciting therapeutic response to agents acting on the growth hormone receptor
NO20052955L (no) Behandling av Huntingtons sykdom med EPA
IN2015KN00290A (zh)
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
WO2004000094A8 (en) Predictive markers in cancer therapy
WO2000050639A3 (en) Gene sequence variations with utility in determining the treatment of disease
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004044163A3 (en) Methods for identifying risk of melanoma and treatments thereof
ATE374838T1 (de) Nukleotidsequenzvariation im gen ns5a als marker
WO2002098355A3 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
AU1955899A (en) Mammalian edg-7 receptor homologs
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling
ITTO20030404A1 (it) Composizione per il ripristino dell'ecosistema vaginale
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
SE0202608D0 (sv) New sequences
TW200617396A (en) Method
AU2003294950A1 (en) Methods and kits for the selection of animals having certain mild production capabilities, based on the analysis of a polymorphism in the growth hormone receptor gene
UA49676A (uk) Спосіб прогнозування гнійно-некротичних ускладнень у хворих на бешиху